grow
bodi
literatur
suggest
chronic
autoimmun
diseas
associ
inappropri
inflamm
mediat
tolllik
receptor
tlr
therefor
research
block
tlr
activ
treat
disord
becom
hot
topic
report
immunomodulatori
properti
nonstimulatori
cpgcontain
oligodeoxynucleotid
cpgodn
previous
known
antagonist
studi
found
vitro
vivo
decreas
level
variou
proinflammatori
factor
induc
singl
activ
coactiv
intracellular
tlr
membranebound
tlr
matter
downstream
signal
pathway
tlr
depend
moreov
attenu
excess
inflamm
imiquimodinduc
psoriasislik
mous
model
skin
inflamm
suppress
immun
cell
infiltr
releas
inflammatori
factor
also
found
evid
immunosuppress
effect
intracellular
tlr
mediat
mechan
result
suggest
act
upstream
signal
cascad
perhap
process
ligand
intern
transfer
taken
togeth
result
suggest
disrupt
variou
aspect
intracellular
tlr
activ
provid
deeper
insight
regul
innat
immun
complex
mechan
drive
pathogenesi
autoimmun
diseas
remain
poorli
understood
drug
current
clinic
use
effect
elimin
autoimmun
diseas
may
caus
side
effect
recent
year
increas
number
studi
shown
innat
immun
disord
close
relat
autoimmun
diseas
pattern
recognit
receptor
prr
innat
immun
system
abl
recogn
pathogenassoci
molecular
pattern
pamp
trigger
relev
signal
transmiss
lead
inflammatori
respons
unfortun
excess
inflamm
induc
autoimmun
diseas
psoriasi
system
lupu
erythematosu
rheumatoid
arthriti
therefor
identif
new
therapeut
target
amelior
autoimmun
pathogenesi
becom
research
prioriti
tolllik
receptor
tlr
famili
protein
express
dendrit
cell
dc
macrophag
constitut
first
line
immunolog
defens
varieti
pathogen
tlr
recogn
specif
pamp
recogn
doublestrand
singlestrand
ss
rna
respect
recogn
unmethyl
cpgdna
receptor
util
variou
downstream
signal
cascad
exampl
depend
trif
pathway
pathway
nevertheless
activ
differ
tlr
induc
similar
proinflammatori
respons
character
releas
factor
tlr
activ
result
format
nodlik
receptor
inflammasom
promot
releas
involv
mani
diseas
tlr
associ
pathway
constitut
interlac
network
make
difficult
identifi
ration
therapeut
target
moreov
excess
inflamm
often
caus
multipl
pamp
thu
coactiv
numer
tlr
add
complex
current
drug
nonselect
target
termin
process
inhibit
result
proinflammatori
factor
antibodi
use
treat
psoriasi
although
therapeut
strategi
shown
promis
also
associ
higher
risk
seriou
infect
contrast
target
upstream
process
could
decreas
side
effect
serv
optim
therapeut
strategi
unfortun
ration
drug
target
yet
identifi
report
new
find
nonstimulatori
cpgcontain
oligodeoxynucleotid
cpgodn
previous
known
antagonist
present
multipl
immunosuppress
effect
intracellular
tlrmediat
activ
result
indic
may
possibl
develop
drug
target
upstream
process
innat
immun
cell
treat
autoimmun
diseas
differenti
mous
bone
marrow
cell
bone
marrowderiv
macrophag
bmdm
bone
marrowderiv
dendrit
cell
bmdc
briefli
bone
marrow
cell
flush
mous
femur
tibia
maintain
lineagespecif
differenti
media
bmdm
maintain
macrophag
differenti
medium
dmem
ngml
mcsf
sigmaaldrich
day
approxim
cell
bmdm
cultur
assess
confoc
imag
analysi
bmdc
maintain
dc
differenti
medium
ngml
gmcsf
ngml
sigmaaldrich
day
approxim
cell
bmdc
cultur
media
supplement
fetal
bovin
serum
hyclon
laboratori
mm
lglutamin
uml
penicillin
streptomycin
cpgodn
purchas
zymosan
agonist
lipopolysaccharid
lp
agonist
sigmaaldrich
polyi
c
agonist
imiquimod
agonist
agonist
invivogen
purchas
agonist
sangon
biotech
china
mix
dotap
n
propyl
n
n
ntrimethylammonium
methyl
sulfat
liposom
transfect
reagent
roch
use
singlestrand
cpgodn
synthes
purifi
sangon
biotech
china
cpgodn
use
studi
includ
cpgodn
measur
concentr
cytokin
cell
cultur
supernat
cytokin
mous
sera
elisa
accord
manufactur
instruct
ebiosci
usa
total
protein
extract
protein
concentr
determin
use
bicinchonin
acid
bca
assay
kit
beyotim
biotechnolog
sampl
protein
separ
sdspage
incub
primari
antibodi
r
system
abcam
tubulin
beyotim
biotechnolog
overnight
follow
horseradish
peroxidaselabel
igg
h
l
beyotim
biotechnolog
normal
level
target
protein
tubulin
membran
scan
xr
system
biorad
usa
induct
treatment
diseas
induc
psoriasi
commerci
avail
aldara
cream
imiquimod
imq
pharmaceut
uk
femal
balbc
mice
week
divid
placebo
treatment
group
administ
phosphat
buffer
salin
pb
placebo
group
g
treatment
group
subcutan
inject
multipl
point
total
topic
appli
mg
imq
cream
shave
back
skin
group
per
day
induct
diseas
perform
consecut
day
pasi
record
daili
three
paramet
thick
erythema
scale
evalu
score
independ
scale
none
slight
moder
mark
mark
cumul
score
sum
three
paramet
rang
histolog
immunofluoresc
histolog
assess
sampl
dorsal
skin
diseas
model
day
fix
formalin
h
embed
paraffin
deparaffin
section
stain
hematoxylin
erythrosin
saffron
assess
light
microscopi
histolog
immunofluoresc
assess
pre
antirabbit
igg
h
l
secondari
antibodi
use
accord
manufactur
instruct
abcam
statist
analysi
data
express
mean
sem
analyz
use
independ
sampl
ttest
p
valu
differ
consid
statist
signific
investig
effect
nonstimulatori
activ
tlr
murin
bmdm
bmdc
suppress
secret
variou
proinflammatori
factor
induc
agonist
polyi
c
respect
induc
agonist
zymosan
lp
figur
b
also
observ
effect
activ
human
monocyt
cell
line
found
also
significantli
suppress
activ
induc
agonist
figur
c
intracellular
receptor
cell
membran
receptor
therefor
data
indic
select
suppress
intracellular
cell
membran
tlr
moreov
investig
effect
cell
two
intracellular
tlr
stimul
simultan
significantli
decreas
proinflammatori
factor
releas
figur
thu
appear
immunosuppress
effect
tlr
coactiv
studi
effect
vivo
balbc
serum
level
elev
hour
treatment
tlr
agonist
significantli
decreas
hour
treatment
figur
b
c
serum
level
elev
third
hour
significantli
decreas
sixth
hour
treatment
figur
treatment
decreas
level
serum
cytokin
time
point
format
activ
tlr
activ
induc
proinflammatori
factor
releas
also
promot
format
inflammasom
investig
effect
basic
element
downstream
effector
molecul
inflammasom
found
lp
increas
express
induc
cleavag
figur
promot
secret
figur
b
interf
inflammasom
activ
induc
decreas
level
cleav
significantli
reduc
releas
figur
interestingli
detect
polyi
cinduc
inflammasom
activ
contrast
previou
report
immunosuppress
effect
specif
recogn
cpgodn
nonstimulatori
molecul
previous
known
antagonist
therefor
investig
immunosuppress
effect
cytokin
secret
downstream
tlr
relat
crosstalk
repeat
vitro
experi
use
bmdm
found
agonist
lost
immunostimulatori
effect
bmdm
howev
could
activ
normal
ligand
interestingli
nonstimulatori
still
abl
significantli
suppress
releas
induc
activ
bmdm
figur
find
indic
immunosuppress
effect
requir
interact
although
agonist
lost
immunostimulatori
function
bmdm
observ
could
significantli
suppress
releas
induc
stimul
figur
b
result
suggest
cpgodn
might
inhibit
activ
regardless
immunostimulatori
properti
relat
attenu
imqinduc
psoriasislik
inflamm
vivo
studi
increasingli
shown
pamp
precipit
factor
psoriasi
psoriasislik
anim
model
develop
investig
effect
model
pasi
score
show
treatment
significantli
decreas
imqinduc
skin
injuri
cours
consecut
day
treatment
figur
contrast
skin
placebo
group
treat
skin
rel
smooth
littl
scale
lighter
erythema
reduc
thick
day
figur
b
patholog
analysi
show
papillari
hyperplasia
reduc
condit
stratum
spinosum
parakeratosi
improv
treatment
group
figur
c
find
indic
attenu
imqinduc
psoriasislik
inflamm
pathogenesi
psoriasi
axi
believ
play
key
role
link
innat
adapt
immun
respons
thu
assess
inflammatori
infiltr
imqdamag
skin
use
immunofluoresc
microscopi
observ
peak
macrophag
infiltr
placebo
group
day
significantli
lower
infiltr
day
figur
first
detect
day
found
increas
express
epiderm
layer
day
figur
likewis
distribut
cell
normal
skin
day
cell
infiltr
increas
epidermi
dermi
day
figur
contrast
treatment
group
reduc
macrophag
infiltr
decreas
releas
attenu
cell
infiltr
research
sought
overcom
chronic
autoimmun
diseas
mani
year
recent
studi
suggest
excess
tlrmediat
inflamm
correl
occurr
progress
diseas
particular
variou
chronic
autoimmun
diseas
close
associ
activ
intracellular
tlr
howev
due
complex
tlr
signal
network
breakthrough
identif
therapeut
target
thu
far
studi
investig
effect
innat
immun
cell
vitro
vivo
significantli
reduc
secret
variou
inflammatori
cytokin
induc
individu
activ
coactiv
intracellular
tlr
also
attenu
inflammatori
infiltr
imqinduc
anim
model
psoriasi
suppress
macrophag
activ
taken
togeth
result
illustr
multipl
immunosuppress
effect
inflamm
mediat
variou
intracellular
tlr
studi
expand
understand
innat
immun
member
tlr
famili
uniqu
structur
featur
recogn
specif
pamp
famili
member
may
character
signal
pathway
use
promot
inflammatori
respons
anoth
point
view
tlr
could
classifi
accord
distribut
cell
unlik
cell
membran
tlr
undergo
direct
activ
intracellular
tlr
requir
addit
step
initi
recognit
includ
ligand
uptak
receptor
circul
studi
demonstr
select
suppress
activ
intracellular
tlr
emphas
function
signific
tlr
distribut
provid
new
strategi
control
excess
inflamm
target
tlr
base
locat
intracellular
tlr
gener
use
distinct
downstream
signal
cascad
signal
trif
pathway
signal
pathway
mediat
immunosuppress
effect
tlr
suggest
mechan
suppress
relat
downstream
signal
cascad
although
crosstalk
common
phenomenon
due
intersect
differ
signal
pathway
studi
indic
immunosuppress
effect
intracellular
tlr
depend
crosstalk
taken
togeth
find
suggest
could
mediat
suppress
effect
act
process
ligand
intern
transfer
upstream
signal
cascad
known
specif
recogn
cpgodn
trigger
proinflammatori
respons
recent
studi
found
mani
cpgodn
immunostimulatori
properti
fact
cpgodn
block
activ
previous
report
screen
larg
collect
nonimmunostimulatori
cpgodn
special
sequenc
structur
outstand
capac
suppress
activ
studi
discov
addit
evid
multipl
immunosuppress
effect
interestingli
found
agonist
similar
immunosuppress
effect
even
immunostimulatori
function
lost
figur
analysi
inflammatori
infiltr
affect
skin
mice
psoriasislik
diseas
laser
confoc
microscopi
antimous
green
dapi
blue
mean
quantiti
cell
per
squar
area
antimous
red
dapi
blue
mean
intens
valu
per
squar
area
antimous
red
dapi
blue
mean
quantiti
cell
per
squar
area
repres
imag
given
three
independ
experi
scale
bar
repres
p
bar
repres
mean
sem
n
characterist
far
pattern
sequenc
function
cpgodn
found
thu
relationship
sequenc
structur
function
remain
ambigu
unlik
immunosuppress
cpgodn
inhibit
subset
intracellular
tlr
contrast
dramat
effect
innat
immun
comparison
current
avail
drug
would
sever
advantag
first
select
inhibit
activ
intracellular
cell
membranebound
tlr
second
block
upstream
event
could
simultan
suppress
multipl
proinflammatori
factor
final
nonstimulatori
natur
would
neg
affect
normal
immun
respons
could
suppress
excess
abnorm
inflamm
help
patient
acut
phase
diseas
studi
demonstr
immunosuppress
effect
inflamm
mediat
variou
intracellular
tlr
upstream
signal
cascad
provid
potenti
approach
regul
innat
immun
without
target
downstream
signal
cascad
